European Commission Vice President Teresa Ribera voices profound shock at the fatal shootings of two protesters in Minneapolis, contrasting with the EU's official cautious stance. Her remarks come as transatlantic tensions simmer over U.S. immigration policies and recent geopolitical threats.
The head of the European Stability Mechanism has told Reuters the bloc's 430-billion-euro emergency fund could be repurposed to provide defense loans to member states, signaling a strategic shift as Europe seeks to bolster its military autonomy.
Shares in Canadian aerospace giant Bombardier plunged 9% following former U.S. President Donald Trump's threat to impose 50% tariffs and decertify its aircraft, escalating trade tensions and sparking alarm across the North American aviation industry.
While mortgage rates have inched up slightly this week, homebuyers are still facing significantly lower borrowing costs compared to last year's peak. We break down the monthly and long-term savings on a typical home purchase.
Denmark's government announced a bold legislative package aimed at expanding deportations and tightening immigration controls, setting the stage for a potential clash with the European Court of Human Rights.
The NBA's Minnesota Timberwolves have released a public statement calling for community solidarity following two separate fatal shootings involving federal immigration agents in Minneapolis, which have sparked protests and renewed debate over immigration enforcement.
Erasca Inc. (ERAS) sees its price target raised from $5 to $12 by Guggenheim, following promising clinical data for its lead oncology candidates and updated financial models. The move comes amid a series of positive analyst revisions for the clinical-stage biopharma firm.
Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.
B.Riley initiates coverage on BrightSpire Capital (BRSP) with a Buy rating, highlighting its robust cash position and improved credit quality as key drivers for future loan originations, while its stock trades at a discount to book value.
ARMOUR Residential REIT (ARR) received a bullish upgrade from Jones Trading, which moved the stock to Buy with a $20.50 target, citing a discounted valuation and expected book value growth compared to agency mortgage REIT rivals.
Analysts at BTIG have upgraded mortgage REIT Annaly Capital Management (NLY) from 'Neutral' to 'Buy', with a $25 price target, arguing the stock is positioned to benefit from dividend stability and potential spread movements in a turbulent interest rate landscape.
LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.
Progress Software Corporation (PRGS) sees bullish sentiment from Wall Street following its Q4 2025 results, with analysts highlighting its growing recurring revenue and strategic positioning in the enterprise software market.
Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.
Analysts at TD Cowen have significantly raised their price target for GE Vernova (GEV) to $780, maintaining a Buy rating after the company's robust Q4 performance exceeded expectations on orders and pricing power.
President Donald Trump announces his intent to nominate former Fed Governor Kevin Warsh as the next Federal Reserve Chair, seeking a leader aligned with his economic vision amid debates over interest rates and inflation.
As severe flooding displaces hundreds of thousands in Mozambique, the UN raises alarms over dangerously overcrowded temporary shelters and a critical funding shortfall, warning of heightened risks for vulnerable populations.
Despite a recent 13% quarterly dip, Digital Turbine (NASDAQ: APPS) has delivered a staggering 116% return to investors over the past twelve months. This surge comes even as the mobile software company remains unprofitable, raising questions about the drivers behind its market optimism and its long-term trajectory.
Eli Lilly bolsters its long-term growth strategy through two new R&D partnerships and a key regulatory milestone for an ovarian cancer drug, signaling a strategic push beyond its blockbuster diabetes and obesity treatments.
Salesforce expands beyond its CRM roots with a landmark $5.6 billion U.S. Army deal and a new joint venture, EMBERPOINT LLC, aiming to apply its AI and cloud platforms to national defense and wildfire response, signaling a major shift into mission-critical public sector infrastructure.
